Pharmaceutical Trade and Supply Chain Survey, Q3 2020 - Coronavirus Disease 2019 (COVID-19) Impact

Pharmaceutical Trade and Supply Chain Survey, Q3 2020 - Coronavirus Disease 2019 (COVID-19) Impact

Summary



This report provides an update on the assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing.

Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the globe.

Scope

  • Report provides in-house analyst expertise on the results of a 5 minute survey of 75 GlobalData Pharma clients and prospects, which was fielded from July 7, 2020 to July 30, 2020.
Reasons to Buy

Objectives included -
  • Benchmark companies’ primary concerns
  • Determine the impact of COVID-19 to date on supply chains
  • Assess companies’ strategic future plans
  • Track changes to corporate strategy and attitudes


Executive Summary
Study Design
Background, Objectives, and Design
Respondent Mix
Primary Business Concerns
Impact of COVID-19 on Company Revenue
Dedicated Planning Team
Supply Chain Concerns
Clinical Trial Materials
Marketed Drugs
Spotlight on US Manufacturing
Import/Export Risks
Clinical Trial Concerns
Addressing Clinical Trial Disruptions
Planning Scenarios
In Their Own Words
Suppliers
Manufacturing Sites
Small Molecule API
Summary
Appendix
.pdf

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook